Accelerated Pharma (Accelerated Pharma) Total Assets : $0.20 Mil (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Total Assets?

Accelerated Pharma's Total Assets for the quarter that ended in Mar. 2017 was $0.20 Mil.

Total Assets is connected with ROA %. Accelerated Pharma's annualized ROA % for the quarter that ended in Mar. 2017 was -1,474.78%. Total Assets is also linked to Revenue through Asset Turnover. Accelerated Pharma's Asset Turnover for the quarter that ended in Mar. 2017 was 0.00.

Accelerated Pharma Total Assets Historical Data

The historical data trend for Accelerated Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Total Assets Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Total Assets

0.50

0.77

0.15

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Total Assets	Get a 7-Day Free Trial			-	0.12	0.21	0.15	0.20

Accelerated Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Accelerated Pharma's Total Assets for the fiscal year that ended in Dec. 2016 is calculated as

Total Assets	=	Total Equity (A: Dec. 2016 )	+	Total Liabilities (A: Dec. 2016 )
	=	-6.403	+	6.55
	=	0.15

Accelerated Pharma's Total Assets for the quarter that ended in Mar. 2017 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2017 )	+	Total Liabilities (Q: Mar. 2017 )
	=	-6.991	+	7.189
	=	0.20

Accelerated Pharma (NAS:ACCP) Total Assets Explanation

Total Assets is connected with ROA %.

Accelerated Pharma's annualized ROA % for the quarter that ended in Mar. 2017 is

ROA %	=	Net Income (Q: Mar. 2017 )	/	( (Total Assets (Q: Dec. 2016 )	+	Total Assets (Q: Mar. 2017 ))	/ count )
	=	-2.544	/	( (0.147	+	0.198)	/ 2 )
	=	-2.544	/	0.1725
	=	-1,474.78 %

Note: The Net Income data used here is four times the quarterly (Mar. 2017) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Accelerated Pharma's Asset Turnover for the quarter that ended in Mar. 2017 is

	Asset Turnover
=	Revenue (Q: Mar. 2017 )	/	( (Total Assets (Q: Dec. 2016 )	+	Total Assets (Q: Mar. 2017 ))	/ count )
=	0	/	( (0.147	+	0.198)	/ 2 )
=	0	/	0.1725
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Accelerated Pharma Total Assets Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines